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It is difficult to over-estimate the enormity of the revolution involved in transitioning 
away from an organ-based system of care (prostatectomy or radiotherapy to 
prostate cancer of any grade, number, location or volume) to one in which the target 
condition is defined and verified, and then subsequently treated with a margin.  
Since Hugh Hampton-Young undertook the first radical prostatectomy over 100 
years ago, an organ-based system of care has been the only plausible strategy for 
men with early prostate cancer.  This is because our risk stratification methods could 
certainly tell us who had prostate cancer when it was indeed identified.  But they 
could not tell us with any degree of precision how much cancer was present 
(number of foci and volume of cancer), what grade it was and where within the 
prostate the cancer resided.  Surgery or radiotherapy to the whole gland, it was 
thought, was a reasonable mitigation (at the cost of over-treatment in a significant 
proportion of men) to the systematic under-estimation of risk to the patient.  The 
degree to which our attempts at risk stratification failed our patients was 
emphasized in a recent UK report that showed a greater than 50% increase in 
histological grade (the most important determinant of risk) at radical prostatectomy 
against the risk the patient was told at the time of diagnosis (1).  ‘Up-grading’ is an 
inverse measure of the quality of our risk stratification.  
 
With this background it should be of little surprise that there remains considerable 
skepticism about our ability to localize disease within the prostate, define it’s volume 
with some degree of precision and identify the worst histological grade within the 
tumour most of the time.  These conditions, which most patients – quite reasonably 
- might expect of a modern cancer diagnostic programme, need to be fulfilled if we 
are to move away from an organ-based strategy for all towards a system of care that 
risk stratifies with precision, treats only those that are likely to benefit and tries to 
preserve tissue and function when we are able to do so.   
 
The technologies and developments that have permitted a reduction in risk 
stratification error from 50% to around 5% are the subject of a paper in this issue (2).  
This group from Australia exploited a cohort of men that underwent a series of tests 
that culminated in a radical prostatectomy.  These comprised: high quality multi-
parametric MRI at a range of magnet strengths; formal scoring or the MRI using an 
ordinal scale of risk; a subsequent 5mm transperineal template guided biopsy 
modified from Winston Barzell’s original account; additional sampling of prostate 
sectors that corresponded to a high likelihood of clinically significant cancer based 
on the MRI reading  - a process otherwise known as ‘targeting’.  The outputs of these 
tests were compared to the presence or absence of clinically significant prostate 
cancer in the 100 prostate lobes evaluated from the 50 eligible men that underwent 
surgery.  The authors’ a priori threshold for declaring clinically significant disease in 
the tests was the presence or a PIRADS 4-5 MRI lesion (with or without concordant 
pathology) and/or the presence of exclusive Gleason pattern 3 amounting to 4mm or 
more maximum cancer core length or the presence of any Gleason pattern 4 or 5 (3).  
At radical prostatectomy slightly different criteria were employed.  Clinically 
significant prostate cancer constituted an exclusive Gleason pattern 3 lesion 
provided it was ≥1.3cc.  The presence of patterns 4 and 5 within the lesion triggered 
‘significance’ as did evidence of capsular invasion or extra-prostatic extension.  
 
Although a small study, the men were exposed to the best diagnostic profile that it was 
possible to have and were subjected to a reference test which most of us would trust.  
 
What did they find?  Just how well did a modern diagnostic panel rule in or rule out 
prostate cancer that exceeded a minimum threshold of 4mm of Gleason pattern 3?  
 
Within the hundred lobes that were evaluated, 21 clinically significant cancers were 
identified in the diagnostic process.  At radical prostatectomy two of these were at the 
midline and therefore attributed - within the rules - to both sides of the gland.  In one of 
these cases there was a 5mm diameter (0.1cc) Gleason 3+4 lesion with 10% Gleason 
pattern 4 that was overlooked by the combined diagnostic process.  A lesion of this 
volume can evade a well-applied sampling strategy based on a 5mm sampling frame, 
especially if the lesion is non-spherical.  The relatively low component of pattern 4 
combined with the relatively low volume means that MRI would also have a hard time 
detecting it.  Under the conditions described in this paper the authors concluded that 
combined MRI and intensive biopsy conferred a sensitivity of 97% and a negative 
predictive value of 91% for a fairly conservative definition of clinically significant disease.  
This level of accuracy, which is nearly twice as good as we were previously capable of, 
will result in major benefits for patients in terms of communicating risk with an order of 
precision that was hitherto not possible.  This should translate to more appropriate 
treatment allocation - both avoiding unnecessary treatment and having treatment when 
it is likely to be beneficial.  It should also result in a significant proportion of patients 
being offered the option of a tissue preserving therapy when it is an option (4).  Most 
importantly, this new precision opens up an opportunity for greater involvement of the 
patient in the process of informed decision-making (5).  Something that was not really 
possible in the face of yesterday’s diagnostic uncertainty.  
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